ECVT & ECCT

23/07/2025

The latest advancement in ECCT shows that well-differentiated adenocarcinoma with a wild-type EGFR mutation dies and changes into a mass with high cholesterol content within 30 minutes of being subjected to an electric field. It is also possible for a 5-cm-diameter lump of recurrent tumor to shrink to normal tissue in two months.

07/07/2025

In 6 months, ECCT removes the primary tumor of high-grade adenocarcinoma of the prostate, as well as all metastatic lymph nodes and bone lesions, with the exception of the area of the face and neck that is uncovered by the device, as seen in this case.

CASE: A 72-year-old French man was diagnosed with prostate cancer with a Gleason score of 9/10 in September 2023. The PET scan results revealed that cancer cells had penetrated the entire prostate gland, spread to lymph nodes in the pelvis and surrounding the aortic blood veins, and reached locations in the hip bones. It was revealed that his disease was already at stage 4.

He then decided to take hormone-suppressing medication while receiving ECT (Electric Cancer Therapy) in Germany and taking the GcMaf immunotherapy supplement from Japan. After about a year of medication, a PET scan revealed that the spread to the lymph nodes had spread to the entire chest and neck area, and the bone spread had reached places up to the skull; meanwhile, the mass in the prostate had completely filled the prostate.

He first used the ECCT device in December 2024. He had no severe concerns while using the ECCT devices. Because the cancer spreads in the form of small points, despite its widespread nature, and the cell type is vulnerable (easily destroyed by an electric field) and the dead cells are relatively easy to leave from the body by excretion such as sweating, urine, and f***s. Even if the cancer has spread far, it can still be completely treated as long as the extended area is well covered by the device.

The PET scan outcomes after 6 months of implementing ECCT revealed that the cancer mass was mostly clean in the prostate and all areas where it spread, including lymph nodes from the pelvis to the chest and all bones, with the exception of the face and neck, which he refused to cover from the start. After reviewing the PET scan results, he agreed to use the new device, which covers his full body, including the face and the neck area. His overall condition is quite normal.

21/06/2025

Case: ECCT for Lung Adenocarcinoma with Positive EGFR Mutation.

A 30-year-old woman was diagnosed with lung cancer in October 2024. She initially complained of heavy, short-breathing and significant chest pain.A core biopsy and EGFR gene mutation screening revealed an adenocarcinoma type with a positive mutation. Her doctor prescribed gefitinib, a targeted therapy tablet, and she began using ECCT practically simultaneously.

The biopsy result indicates no tissue differentiation. The response of ECCT to adenocarcinoma cancer cell types is determined by the cells' electrical polarity, which correlates with their malignancy grade. For high-grade (high electrical polarity, e.g., undifferentiated adenocarcinoma), 70-80% of the tumor mass (independent of size) can be reduced in 1-3 months. The intermediate grade shrinks by 40-50% within 3-6 months. Low-grade (well-differentiated adenocarcinoma) requires 6-12 months to achieve a 20-30% decrease. Combining with targeted drug administration often improves the efficacy of the therapy while minimizing inflammation, especially when the mass volume is substantial.

Her response to the combination therapy was relatively positive and speedy. Her complaints of shortness of breath and soreness subsided within a month. The progress of ECCT treatment is generally determined by the smoothness of the excretion process. In her case, the majority of the elimination was through thick phlegm. Along with the smooth release of excessive and thick phlegm, her condition has improved, and her complaints have steadily lessened. The CT scan results after three months of use revealed a mass reduction of approximately 30-40% by volume. The response is consistent with a medium- to high-grade adenocarcinoma.

After 6 months of using the device, her symptoms have mostly vanished. She resumed her everyday routines as usual. The CT scan results suggest that the tumor mass has shrunk further, down to 50% of its original size. Her lungs retain some fluid, but her overall health and condition are just fine.

02/06/2025

CASE: High-grade adenocarcinoma with EGFR-positive mutation treated with ECCT and targeted drug.

The 76-year-old Mr. Hasni was initially diagnosed with lung cancer in his right lung, which was 2X6X3 cm. The biopsy revealed an EGFR mutation-positive adenocarcinoma type. The doctor had originally intended to operate but canceled it after discovering metastases in both the left and right lungs. The sole medication that was administered to him was Tagrisso.

After two months of targeted drug prescription, a CT scan examination revealed that the cancer had continued to grow quickly, reaching 4X7X4 cm, three times its original volume, and that the dissemination in both lung fields had become more widespread. Additionally, Mr. Hasni's health is deteriorating. He then combined the specific oral medication with ECCT. Highly malignant cancer cells are killed by the ECCT device in a short period of time (one to three months), and the targeted chemotherapy medication successfully inhibits the endocytosis response, facilitating a seamless and efficient procedure and averting a cytokine storm that would otherwise cause extensive inflammation.

Following three months of ECCT cancer treatment, Mr. Hasni's tumor shrank to 1X2X1.5 cm, a 97% reduction in size; the spread also became much less pronounced. Six months of continuous use of the device further decreased the cancer mass to the calcium residue that remained. He is currently in normal condition and in excellent health at the age of 77.

08/05/2025

CASE: ECCT combined with radiation therapy for stage 4 lung adenocarcinoma

Low-grade, well-differentiated adenocarcinoma with EGFR wild-type mutation responds slowly to ECCT. However, when combined with radiation therapy, it results in dramatic shrinking of this stage-4 lung cancer that has already infiltrated the muscle by 80-90% of its volume in 6 months. ECCT was utilized both before and after radiation therapy to provide long-term protection and prevent recurrence and metastasis. CT scan after 9 months with continued usage of ECCT showed further reduction in the tumor mass. The clinical condition of the patient is relatively normal.

25/04/2025

CASE: Low grade lung adenocarcinoma with ECCT combined with Chemotherapy

Low-grade adenocarcinoma often responses slowly to ECCT treatment. However, combining ECCT with chemotherapy after 2-3 months of use reveals a considerable reduction of 70-80% by volume in 6 months in a case of a 52-year-old male diagnosed with well-differentiated (low grade) adenocarcinoma with EGFR-negative mutation.

09/03/2025

Survival rate for the most malignant brain cancer, glioblastoma multiform (GBM) with ECCT is among the highest according to statistical study published on Japanese Journal of Aging and Regenerative Medicines 2024.

国際抗老化再生医療学会雑誌 第 6 巻（20−33）2024
By Shinichiro Akiyama, MD, PhD, FACP
Cancer gene& Immunotherapy Expert
Clinical Oncology, McGill University, CANADA
Faculty of Science and Technology, Keio University, JAPAN

Mechanism of Action
Electro Capacitive Cancer Therapy (ECCT) employs low-voltage, medium-frequency electric fields to disrupt mitotic progression by inducing microtubule depolymerization, ultimately triggering apoptosis in cancer cells while sparing normal tissues. By interfering with the electrostatic forces that stabilize spindle formation during cell division, ECCT selectively targets proliferating malignant cells without the systemic toxicity associated with conventional therapies such as chemotherapy and radiotherapy.

Preclinical Evidence
In vitro and in vivo studies have demonstrated ECCT’s efficacy in suppressing tumor growth, with research indicating a 28–39% reduction in cancer cell proliferation and significant tumor shrinkage in murine models. Further investigations have revealed ECCT-mediated downregulation of IL-18 and CCL-2, key inflammatory cytokines implicated in tumor progression, as well as p53-independent p21 pathway activation leading to apoptosis in osteosarcoma cells. These findings highlight ECCT’s potential as a targeted, non-cytotoxic oncologic intervention.

Clinical Evidence
ECCT has shown promising outcomes in multiple malignancies, including glioblastoma multiforme (GBM), breast cancer, lung cancer, and lymphoma, as evidenced by a retrospective analysis of 5,195 patients. A Kaplan-Meier survival analysis in GBM patients revealed a median overall survival (OS) of 28.9 months for ECCT-treated individuals versus 15.6 months for those receiving Temozolomide (TMZ) alone, suggesting superior efficacy with ECCT. Furthermore, ECCT’s safety profile was highly favorable, with no high-grade systemic toxicity reported and only mild, localized discomfort in select cases.

Tumor Response Classification
Electrical Capacitance Volume Tomography (ECVT) has enabled the stratification of tumor responses into five categories, with soft, medium-to-high-grade tumors exhibiting the most favorable responses to ECCT, while highly aggressive phenotypes necessitate extended monitoring due to rapid metastatic potential. These findings suggest that ECCT may be particularly effective in certain tumor subtypes, warranting further investigation into
patient selection criteria.

Future Directions
As a non-invasive, well-tolerated therapeutic modality, ECCT holds significant potential for patients with advanced, refractory, or chemotherapy-intolerant malignancies. Future research will focus on optimizing treatment parameters, investigating synergies with immune checkpoint inhibitors, and conducting large-scale, randomized clinical trials to establish ECCT as a paradigm-shifting oncologic intervention with broad clinical applicability.
If validated through further studies, ECCT could redefine the landscape of cancer treatment by offering a novel, mechanistically distinct alternative to conventional cytotoxic therapies.

Source: https://waarm.or.jp/paper/ecct-physical-therapy-for-cancer-clinical-report/

05/02/2025

01/05/2024

Semua cara telah ditempuhnya, termasuk operasi mutakhir dengan Gamma Knife, berakhir tak bisa bicara, komunikasi, maupun jalan. Alternatif terakhir yang mungkin tersisa saat itu adalah ECCT. Tipe tumor yang dialami Bu Masturoh adalah campuran komponen padat ganas dan kista, secara respon terhadap medan listrik yang dihasilkan oleh ECCT sifatnya juga campuran: Komponen padat merespon terhadap ECCT tergantung tingkat keganasan, semakin ganas (semakin cepat berkembang) semakin cepat merespon medan listrik, relatif cepat mengalami kematian, meluruh dan menyusut secara perlahan. Sementara komponen kistik pada dasarnya bukan sel yang hidup, tak merespon paparan medan listrik seperti sel padat yang tumbuh. Dengan alat ECCThasil pengembangan terbaru, alat juga bisa berperan sebagai p***a, membuka kanal ion pada membran kista, membantu mengalirkan cairan dan molekul material di dalam kista ke luar selaput, mirip efek membuka blood-brain barrier, kista bisa mengecil.

Modulasi medan listrik pada alat ECCT hasil pengembangan terbaru menunjukkan respon yang cukup efektif pada kasus Ibu Masturoh yang sebelumnya sulit ditangani dengan alat ECCT dengan spesifikasi lama. Setelah 2 bulan pakai alat ECCT, 8 bulan setelah tak bisa bicara dan jalan harus didorong di kursi roda, bicara dan jalan Bu Masturoh sudah kembali normal.

Semoga tetap sehat buat Bu Masturoh.

Bulan April2023 Bu Masturoh datang ke Lab C-Care Riset kanker (Riset kanker DR. Warsito) dalam kondisi didorong di kursi roda, bicara sulit...